




Shaping a Healthier Future: Body Composition Changes and Clinical Improvements in Pediatric Cystic Fibrosis Patients on Lumacaftor/Ivacaftor Therapy: a 24-month Real-World Study

Imrei Marcell, Kéri Adrienn, Gács Éva, Gönczi Ildikó, Meláth Melinda, Kosaras Éva, Demeter Botond, Péterfia Csaba, Vass Klára, Székely Gyöngyi, Ocskay Klementina, Párniczky Andrea

Imrei Marcell
MGYGT2024




A diagram illustrating a stepped wedge design for a clinical trial. It features four treatment groups represented by colored rectangles. At the top, a yellow triangle points to the right. Below it, a large yellow rectangle represents the 'Elexacaftor + Tezacaftor + Ivacaftor' group. Within this yellow rectangle, there is a smaller teal rectangle representing the 'Lumacaftor + Ivacaftor' group. Below the yellow rectangle is a teal rectangle representing the 'HT saline' group. At the bottom is another teal rectangle representing the 'Azthromycin' group.

Elexacaftor
+ Tezacaftor
+ Ivacaftor



Lumacaftor + Ivacaftor

HT saline


Azthromycin



Antropometriai adatok



Antropometriai adatok




Testösszetétel

	Össz	2-5	6-12	13<
Zsír%	11 (9, 17)	8 (3, 17)	15 (10, 17)	11 (9, 16)
Vázizom%	43 (39, 47)	40 (38, 43)	43 (39, 45)	48 (42, 50)




	Össz	2-5	6-12	13<
Zsír%	15 (12, 22)	19 (15, 25)	18 (15, 21)	12 (8, 14)
Vázizom%	42 (40, 49)	39 (34, 42)	41 (40, 45)	49 (46, 51)



zsír%




vázizom%



Pankretikus elasztáz



Pankretikus elasztáz






Útravaló tudnivaló


- BMI növekszik
- Testzsírszázalék nő -> normal-weight obesity!
- Pancreas exokrín funkció javul

Köszönöm a figyelmet





SwCl



BMI

